摘要
目的
观察靶向干扰前列腺癌抗原-1(PCA-1)表达对前列腺癌裸鼠移植瘤的影响。
方法
培养人前列腺癌LNCaP细胞并将其注射到裸鼠皮下建立前列腺癌裸鼠移植瘤模型。将裸鼠随机分为实验组和对照组,实验组：将靶向干扰PCA-1表达的重组质粒PSMAe/p-PCA-1-pA-Sliencer注射到裸鼠移植瘤局部和周围,对照组：将PBS注射到移植瘤局部和周围；观察移植瘤生长情况和实验结束时肿瘤的大小。应用免疫组织化学方法和常规病理技术观察肿瘤组织中PCA-1表达情况以及裸鼠主要器官的病理变化。
结果
实验组裸鼠移植瘤生长速度明显慢于对照组,差异具有统计学意义(P<0.05)；实验结束时实验组和对照组的移植瘤体积(cm3)分别为1.142±0.157和3.086±0.265,差异有统计学意义(P<0.05)。实验组裸鼠的主要器官未出现明显病理变化。实验组裸鼠移植瘤组织PCA-1蛋白染色平均总积分(3.8±1.48)高于对照组(6.2±2.48),差异具有统计学意义(P<0.05)。
结论
成功建立前列腺癌裸鼠移植瘤模型,靶向干扰PCA-1表达可以抑制移植瘤的生长,对裸鼠主要器官未产生明显影响。
Objective
To observe role of targeting inhibition of prostate cancer antigen-1expression for prostate cancer xenografts in nude mice.
Methods
We inject human prostate cancer LNCaP cells into subcutaneous tissue of nude mice to establish prostate cancer xenografts in nude mice. The mice were randomly divided into experimental and control groups. Experimental group:the recombinant plasmid PSMAe/p-PCA-1-pA-Sliencer was injected into xenografts of nude mice to target to interfere with the PCA-1expression. Control group:PBS injected into the local and around xenografts of nude mice. We observed the growth speed of xenografts and the size of xenografts at the end of the experiment. We applied immunohistochemical methods and conventional pathology to observe the PCA-1expression in xenografts of nude mice and pathological changes in major organs of nude mice.
Results
The growth speed of xenografts in experimental group was significantly slower than that in control group (P<0.05). At the end of the experiment, the volume of xenografts in experimental group and control group (cm3) were respectively1.142±0.157and3.086±0.265, the difference was statistically significant (P<0.05). The main organs of nude mice in the experimental group does not appear significant pathological changes. The average total score of PCA-1protein staining in experimental group (3.8±1.48) is higher than that in control group (6.2±2.48)(P＜O.05).
Conclusion
We have successfully established prostate cancer xenografts in nude mice, targeted interference with the PCA-1expression can inhibit tumor growth and did not significantly affect the major organs of nude mice.
引文
[1]Konishi N, Nakamura M, Ishida E, et al. High expression of a new marker PCA-1 in human prostate carcinoma [J]. Clin Cancer Res,2005,11(14):5090-5097.
[2]Rachelle RO, Ivy C, Bruce RZ. Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo. Amino Acids,2012,42:549-558.
[3]Laura SS, Ramaprasad S, Linehan WM. The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies[M]. Renal Cell Carcinoma, Part 1,2012, Pages 3-25.
[4]Axel B, Tamara E, Florry VD, et al. Immunological Heterogeneity of the RCC Microenvironment:Do Targeted Therapies Influence Immune Response[J]? Current Oncology Reports,2012, Online FirstTM,23 February.
[5]Lise Willems, Jerome Tamburini, Nicolas Chapuis, et al. PI3K and mTOR Signaling Pathways in Cancer:New Data on Targeted Therapies[J]. Current Oncology Reports,2012, 14:129-138.
[6]Junjie Li, Feng Chen, Marlein Miranda Cona, et al. A review on various targeted anticancer therapies[J]. Targeted Oncology,2012,7:69-85.
[7]Qiang Liu, XiaoShi Zhang, YiXin Zeng. Targeted and personalized therapy for cancer: Theory and practice in China[J]. SCIENCE CHINA Life Sciences,2011,54:1081-1084.
[8]Matthias Preusser, David Capper, Aysegiil Ilhan-Mutlu, et al. Brain metastases: pathobiology and emerging targeted therapies[J]. Acta Neuropathologica,2012,123: 205-222.
[9]Kai Wang, Jin Wei. Multi-targeted therapies in non-small cell lung cancer[J]. Clinical Oncology and Cancer Research,2011,8:220-223.
[10]Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia[J]. Nature,2011,478:524-528.
[11]Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature,2011,470:214-220.
[12]12 Maira, Francesca, Catania Alessia, Candido Saverio, et al. Molecular Targeted Therapy in Melanoma:A Way to Reverse Resistance to Conventional Drugs[J]. Current Drug Delivery,2012,9:17-29.
[13]Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer[J]. Science 2002; 296:1046-1049.
[14]Navin N, Kendall J, Troge J, et al.Tumour evolution inferred by single-cell sequencing[J]. Nature 2011,472:90-94.
[15]Manfred Westphal, Katrin Lamszus. Targeted Therapies.2010, Oncology of CNS Tumors, Part Ⅰ, Pages 77-85.
[16]Martine J. Piccart-Gebhart, Ahmad Awada. Targeted therapies for solid tumors:is the dream becoming a reality? [J] Targeted Oncology,2006,1:113.
[17]Howard West. The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer[J]. Current Oncology Reports,2011,13:280-289.
[18]Benyi Li. Prostate Cancer Targeted Therapy[J]. Encyclopedia of Cancer,2012,16: 3062-3064.
[19]Claus M Schlotter, Ulf Vogt, Heike Allgayer, et al. Molecular targeted therapies for breast cancer treatment [J]. Breast Cancer Research,2008,10:211.
[20]Gaetan des Guetz, Bernard Uzzan, Kader Chouahnia. Cardiovascular toxicity of anti-angiogenic drugs. Targeted Oncology,2011,6:197-202.
[21]Winson Y. Cheung. Cardiac Toxicities of Cancer Therapies:Challenges for Patients and Survivors of Cancer.2011, The MASCC Textbook of Cancer Supportive Care and Survivorship, Part 3, Pages 73-82.
[22]Biagio Agostara, Giuseppe Carruba, Antonella Usset. The management of cancer in the elderly:targeted therapies in oncology[J]. Immunity & Ageing,2008,5:16.
[23]Flora Kyriakou, Panteleimon Kountourakis, Demetris Papamichael. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients [J], Targeted Oncology, 2011,6:245-251.
[24]Scott AS, Anand K, Andrew JB. Common toxicities of mammalian target of rapamycin inhibitors[J]. Targeted Oncology,2011,6:125-129.
[25]David Siu. Cancer therapy using tumor-associated antigens to reduce side effects[J]. Clinical and Experimental Medicine,2009,9:181-198.
[26]Stephanie Biri, Fabrice Stock, Abdennaji Adib, et al. Delivery of Biomolecules with Non-Viral Vectors[J]. ESACT Proceedings,2010,4:115-119.
[27]Patrick Michl, Thomas M. Gress. Pancreatic cancer-Outlook:targeted therapy. [J] The Chinese-German Journal of Clinical Oncology,2007,6:176-180.
[28]Juergen Mairhofer, Reingard Grabherr. Rational Vector Design for Efficient Non-viral Gene Delivery:Challenges Facing the Use of Plasmid DNA[J]. Molecular Biotechnology, 2008,39:97-104.
[29]EI-Aneed A. An overview of current delivery systems in cancer gene therapy[J]. J Control Release.2004,94:1-14.
[30]Kochanek S, Schiedner G, Volpers C. High-capacity"gutless"adenoviral vectors[J]. Curr Opin Mol Ther,2001,3:454-463.
[31]Ernst-Jurgen Schlaeger, Eric A. Kitas, Arnulf Dorn. SEAP expression in transiently transfected mammalian cells grown in serum-free suspension culture[J]. Cytotechnology, 2003,42:47-55.
[32]E. Berezhnoy, A. A. Wainson, N. N. Kasatkina, et al. High-dose y-irradiation enhances the expression of a transgene controlled by the immediate-early CMV promoter in stably transfected tumor cells[J]. Molecular Biology,2008,42:442-448.
[33]Süleyman Ergun, Nerbil Kilic, Jan-Henner Wurmbach, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes [J]. Angiogenesis,2001,4: 193-206.
[34]Ran Li, Hong Chen, Chang-shan Ren. Growth inhibition of breast cancer in rat by AAV mediated angiostatin gene[J]. Chinese Journal of Cancer Research,2007,19:108-112.
[35]Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane expression is greatest in prostate adenocarcinoma and lymph node metastases[J]. Urology,1998,52(4):637-640.
[36]Zeng H, Wu Q, LI H, et al. The construction of recombinant plasmids with prostate-specific membrane antigen(PSMA) promote controlling reporter expression[J]. J Sichuan Univ(Med Sci Edi),2005,36(2):169-171.
[37]徐勇PSMA增强子/启动子驱动shRNA靶向干扰核干因子治疗前列腺癌的研究[D].天津,天津医科大学,2008.
[38]Zeng H, Wu Q, Li H, et al. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer [J]. J Androl,2005,26(2):215-221.
[39]Gregorakis AK, Holmes EH, Murphy GP. Prostate specific mem-brane antigen:current and future utility [J]. SeminUrol Oncol,1998,16(1):2.
[40]Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma:an immunhistochemical study using mutiple tumour tissue microarray technique[J]. Histopathology,2007,50 (4):472-475.
[41]刘秉乾,武玉东,魏金星等.前列腺癌组织中前列腺癌抗原-1的表达及临床意义[J].中华男科学杂志,2007,13(11)：997-1001.
[42]Liu BQ, Wu YD, Li PH, et al. Prostate cancer antigen-1 as a potential novel marker for prostate cancer Asian Journal of Andrology[J]. Asian Andro J,2007,9:821-826.
[43]Konishi N, Nakamura M, Ishida E,et al. High expression of a new marker PCA-1 in human prostate carcinoma [J]. Clin Cancer Res,2005,11(14):5090-5097.
[1]马春光,叶定伟,姚旭东,等.转移性前列腺癌生存预后分析.中华外科杂志,2010,15：1166-1169.
[2]徐勇,张志宏.我国前列腺癌的临床热点问题探讨.中华泌尿外科杂志,2011,9：585-587.
[3]马春光,叶定伟,姚旭东,等.前列腺癌的流行病学特征及晚期一线内分泌治疗分析.中华外科杂志,2008,12：921-925.
[4]叶定伟,李长岭.前列腺癌发病趋势的回顾和展望.中国癌症杂志,2007,3：177-180.
[5]叶定伟.前列腺癌的流行病学和中国的发病趋势.中华外科杂志,2006,6：362-364.
[6]Joan Carles, Daniel Castellano, Miguel Angel Climent, et al. Castration-resistant metastatic prostate cancer:current status and treatment possibilities. Clinical and Translational Oncology,2012,14:169-176.
[7]Michela Biancolella, Alessandra Valentini, Daniela Minella, et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Investigational New Drugs,2007,25:491-497
[8]Christopher F Sharpley, Vicki Bitsika, David R Christie. The role of Melancholia in prostate cancer patients'depression. BMC Psychiatry,2011,11:201.
[9]Rachelle R. Olsen, Ivy Chung, Bruce R. Zetter. Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo. Amino Acids,2012,42:549-558.
[10]M. Tangney, G. Casey, J. O. Larkin, et al. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. Cancer Immunology, Immunotherapy,2006,55:1443-1450.
[11]Keri L. Nowend, Alison N. Starr-Moss and Keith E. Murphy. The function of dog models in developing gene therapy strategies for human health. Mammalian Genome,2011,22: 476-485.
[12]Birgit Kantor, John Altman, Robert S. Simari, et al. Gene therapy for myocardial angiogenesis:Has it come of age? Current Atherosclerosis Reports,2000,2:373-379.
[13]Yue Chen, Gang Wang, Deling Kong, et al. In vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line. World Journal of Surgical Oncology,2012,10:3.
[14]Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature,2011,478:524-528.
[15]Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature,2011,470:214-220.
[16]Maitland N, Stanbridge L, et al. Targeting Gene Therapy for Prostate Cancer. Curr Pharmac Des,2004,10:531-555
[17]Aline A Fiebig, Weijia Zhu, Catherine Hollerbach, et al. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer,2006,6:213.
[18]Konishi N, Nakamura M, Ishida E, et al. High expression of a new marker PCA-1 in human prostate carcinoma. Clin Cancer Res,2005,11:5090-5097.
[19]Christoph-Erik Mayer, Barbara Haigl, Florian Jantscher, et al. Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cellular and Molecular Life Sciences,2010,67:3299-3311.
[20]Gongyuan Zhang, Qiao Zhang, Qinxian Zhang, Lei Yin and Shenglei Li, et al. Expression of Nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. Journal of Cancer Research and Clinical Oncology,2010,136:587-594.
[21]Shengjie Guo, Xiaopeng Mao, Junxing Chen, Bin Huang and Chu Jin, et al. Overexpression of Pim-1 in bladder cancer. Journal of Experimental & Clinical Cancer Research,2010,29:161.
[22]Andre O von Bueren, Christoph Oehler, Tarek Shalaby, Katja von Hoff and Martin Pruschy, et al. c-MYC expression sensitizes medulloblastoma cells to radio-and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer,2011,11:74
[23]Klas G Wiman. New p53-based anti-cancer therapeutic strategies. Medical Oncology,1998, 15:222-228.
[24]Yoshihiko Kadowaki, Nikhil S. Chari, Albert E. K. Teo, Akihiko Hashi and Kevin B. Spurgers, et al. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells. Apoptosis,2011,16: 627-635.
[25]T. V. Kekeeva, O. P. Popova, P. V. Shegai, B. Ya. Alekseev and Yu. Yu. Andreeva, et al. Aberrant methylation of p16, HIC1, N33, and GSTP1 in tumor epithelium and tumor-associated cells in prostate cancer. Molecular Biology,2007,41:70-76.
[26]Shalev M, et al. Gene therapy for prostate cancer. Urology,2001,57(1):8-16.
[27]J. Zhang and S. J. Russell. Vectors for cancer gene therapy. Cancer and Metastasis Reviews, 1996, Volume 15, Number 3, Pages 385-401
[28]Stephanie Biri, Fabrice Stock, Abdennaji Adib and Patrick Erbacher. Delivery of Biomolecules with Non-Viral Vectors. ESACT Proceedings,2010,1, Volume 4, Cells and Culture, Part 3, Pages 115-119.
[29]Juergen Mairhofer and Reingard Grabherr. Rational Vector Design for Efficient Non-viral Gene Delivery:Challenges Facing the Use of Plasmid DNA. Molecular Biotechnology, 2008,39:97-104.
[30]Chong-Kook Kim and Dong-Kyu Park. Stability and drug release properties of liposomes containing cytarabine as a drug carrier. Archives of Pharmacal Research,198710:75-79.
[31]Li S, Huang L.Nonvirul gene therapy:promises and challenges. Gene Ther,2000,7(1): 31-34.
[32]Karin Moiling. Naked DNA for vaccine or therapy. Journal of Molecular Medicine,1997, 75:242-246.
[33]Virginia Cebrian, Clara Yagüe, Manuel Arruebo, et al. On the role of the colloidal stability of mesoporous silica nanoparticles as gene delivery vectors. Journal of Nanoparticle Research,2011,13:4097-4108.
[34]Shokyoku Kanaoka, Nobuhiro Hayase and Toshinobu Higashimura. Synthesis of star-shaped poly(vinyl ether)s by living cationic polymerization:Pathway for formation of star-shaped polymers via polymer linking reactions. Polymer Bulletin,2000,44:485-492.
[35]EI-Aneed A,An overview of current delivery systems in cancer gene therapy. J Control Release.2004,94:1-14.
[36]Kochanek S, Schiedner G,Volpers C.High-capacity"gutless"adenoviral vectors. Curr Opin Mol Ther.2001,3:454-463.
[37]Herman JR,Adler HL,Aguilar CE,et al.In situ gene therapoy for adenocarcinoma of the prostate:a phase 1 clinical trial. Hum Gene Ther,1999,10:1239-1249.
[38]Fumihiko Kanai. Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector. Molecular Biotechnology,2001, Volume 18, Number 3, Pages 243-250
[39]Volpers G,Kochanek S.Adenoviral vectors for gene transfer and therapy.J Gene Med.2004, Suppll:S164-171.
[40]Jacov Tal. Adeno-associated virus-based vectors in gene therapy. Journal of Biomedical Science,2000,7:279-291.
[41]Song S,Goudy K,Campbell-Thompson M,et al.Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type 1 diabetes in NOD mice. Gene Ther,2004,11:181.
[42]ChuD, Sullivan CC, WeitzmanMD, et al.Direct comparison of efficiency and Stability of gene tarnsfer into the mammalian heart using adeno-associated Viurs versus adenovirus vectors.Thorac Cardiovasc Surg,2003,126:671-679.
[43]Weiss R. Viral RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Rev Med Virol,1998,8:3-11.
[44]Boegrer AL, Snitkovsky S, Young AJ. Retroviral vectors preloaded with a viral receptor-lignad bridge protein are targeted to specific cell tpyes. Proc Natl Acad sci USA, 1999,96:9867-9872.
[45]Mitchell R S, Beitzel B F, Schroder A R W, et al.Retroviral DNA integration; ASLV, HIV,and MLV show distinct target site preferences. PloS Biology,2004,2:1127-1137.
[46]Bleck GT. An alternative method for the rapid generation of stable,high-expressing mammalian cell lines. Bioprocessing Journal,2005,4:43-51.
[47]Andrea Gambotto, Seon Hee Kim, Sunyoung Kim and Paul D. Robbins. Methods for Constructing and Producing Retroviral Vectors. Methods in Molecular Biology,2000,1, Volume 135, Developmental Biology Protocols, VIII, Pages 495-508.
[48]Walker JR, McGeagh KG, Sundaresan P. et al. Hum Gene Ther,1999,10:2237.
[49]Blank SV, Rubin SC, Coukos G, et al. Replication-selective herpes simplex virus thpe 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther, 2002,13:627-639.
[50]Cornel Fraefel, Peggy Marconi and Alberto L. Epstein. Herpes Simplex Virus Type 1-Derived Recombinant and Amplicon Vectors. Methods in Molecular Biology,2011,1, Volume 737, Viral Vectors for Gene Therapy, Pages 303-343
[51]David S. Latchman. Herpes simplex virus vectors for gene therapy. Molecular Biotechnology,1994,2:179-195.
[52]Matono S, Tanaka T, Sueyoshi S, et al. Bystander effect in suicide gene therapy is directly prorortional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol,2003,23:1309-1315.
[53]inocchiaro LM, Bumaschny VF, Karara AL, er al. Herpes simplex virus thymidine kinase/ganciclovir system in multicellular tumor spheroids. Cancer Gene Ther,2004,11(5): 333-345.
[54]Yoshimura I, Ikegami S, Suzuki S, et al. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol,2O02,168:2659-2664.
[55]Yue Chen, Gang Wang, Deling Kong, Zhihong Zhang and Kuo Yang, et al. In vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line. World Journal of Surgical Oncology,2012,10:3.
[56]Song Fei, Xing Qi, Song Kedong, Ji Guangchun and Liu Jian, et al. The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. Journal of Cancer Research and Clinical Oncology,2012,138: 347-357.
[57]Uchida A, O'Kee fe DS, Bacich DJ, et al. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer:a potential alternative approach to androgen deprivation therapy. Urology,2001,58:132-139.
[58]Yoshimura I, Ikegami S, Suzuki S, et al. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Gre-loxP system. J Urol,2002,168:2659-2664.
[59]Easthaln JA, Chen SH, Sehgal 1, et al. Prostate cancer gene therapy:herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther,1996,7(4):515-523.
[60]Latham JP, Searle PF, Mautner V, et al. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer:construction and testing of tissue-specific adenovirus veetor. Cancer Res.2000,60(2):334-341.
[61]http://shiyan.ebioe.com/5221.htm
[62]Dirk Grimm. The dose can make the poison:lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence,2011,2:8.
[63]Sailen Barik. Silence of the transcripts:RNA interference in medicine. Journal of Molecular Medicine,2005,83:764-773
